Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer

2017 ◽  
Vol 5 (8) ◽  
pp. 1522-1525 ◽  
Author(s):  
Bing Feng ◽  
Fangyuan Zhou ◽  
Wenchao Lu ◽  
Dangge Wang ◽  
Tingting Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Drug Loading ◽  
High Drug ◽  
Loading Ratio ◽  
High Drug Loading

An oxaliplatin prodrug liposome with an extremely high drug loading ratio (>27%) was reported for treatment of triple-negative breast cancer.

Micellar nanoformulation of lipophilized bortezomib: high drug loading, improved tolerability and targeted treatment of triple negative breast cancer

2017 ◽  
Vol 5 (28) ◽  
pp. 5658-5667 ◽  
Author(s):  
Kaiqi Wu ◽  
Ru Cheng ◽  
Jian Zhang ◽  
Fenghua Meng ◽  
Chao Deng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Drug Loading ◽  
Targeted Treatment ◽  
High Drug ◽  
Micellar Systems ◽  
Efficacious Drug ◽  
High Drug Loading

Lipophilization of bortezomib with pinanediol enables efficacious drug loading and targeted tumor chemotherapy with reduction-sensitive self-crosslinked micellar systems.

Application of composite dissolving microneedles with high drug loading ratio for rapid local anesthesia

2018 ◽  
Vol 121 ◽  
pp. 330-337 ◽  
Author(s):  
Haohui Zhan ◽  
Fengsen Ma ◽  
Yingcong Huang ◽  
Jie Zhang ◽  
Xiayun Jiang ◽  
...  
Keyword(s):  
Local Anesthesia ◽  
Drug Loading ◽  
High Drug ◽  
Dissolving Microneedles ◽  
Loading Ratio ◽  
High Drug Loading

scholarly journals Preparation of high drug-loading celastrol nanosuspensions and their anti-breast cancer activities in vitro and in vivo

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Tiantian Huang ◽  
Yian Wang ◽  
Yiping Shen ◽  
Hui Ao ◽  
Yifei Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Loading ◽  
High Drug ◽  
High Drug Loading

Identification of new therapeutic leads for triple negative breast cancer subtypes

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
AJ Robles ◽  
L Du ◽  
S Cai ◽  
RH Cichewicz ◽  
SL Mooberry
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Therapeutic Leads

Immediate and long-term results of the first line chemotherapy in patients with metastatic triple negative breast cancer. Final analysis of randomized study

2020 ◽  
pp. 75-80
Author(s):  
S.A. Lyalkin ◽  
◽  
L.A. Syvak ◽  
N.O. Verevkina ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Randomized Study ◽  
Progression Free Survival ◽  
First Line ◽  
Free Survival ◽  
Group 2 ◽  
Line Chemotherapy ◽  
Group 1

The objective: was to evaluate the efficacy of the first line chemotherapy in patients with metastatic triple negative breast cancer (TNBC). Materials and methods. Open randomized study was performed including 122 patients with metastatic TNBC. The efficacy and safety of the first line chemotherapy of regimens АТ (n=59) – group 1, patients received doxorubicine 60 мг/м2 and paclitaxel 175 мг/м2 and ТР (n=63) – group 2, patients received paclitaxel 175 мг/м2 and carboplatin AUC 5 were evaluated. Results. The median duration of response was 9.5 months (4.5–13.25 months) in patients received AT regimen and 8.5 months (4.7–12.25 months), in TP regimen; no statistically significant differences were observed, р=0.836. The median progression free survival was 7 months (95% CI 5–26 months) in group 1 and 7.5 months (95% CI 6–35 months) in group 2, p=0.85. Both chemotherapy regimens (AT and TP) had mild or moderate toxicity profiles (grade 1 or 2 in most patients). No significant difference in gastrointestinal toxicity was observed. The incidence of grade 3–4 neutropenia was higher in patients of group 2 (TP regimen): 42.8% versus 27% (р<0.05). Conclusions. Both regimens of chemotherapy (AT and TP) are appropriate to use in the first line setting in patients with metastatic TNBC. Key words: metastatic triple negative breast cancer, chemotherapy, progression free survival, chemotherapy toxicity.

Sign in / Sign up

Export Citation Format

Share Document